Clinical trials: Kerato Conjunctivitis Sicca
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Sjogren Syndrome
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments
- Trial name
- NCT05124925
- Testing
- Ianalumab
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Keratoconjunctivitis Sicca
Tear Film Break-up Time After Instillation of Artificial Tears
This study is an exploratory trial evaluating the tear film break-up time after a single eye drop instillation of over-the-counter artificial tears.
- Trial name
- NCT00681265
- Testing
- glycerin, polyethylene glycol 400/propylene glycol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Calm Water Therapeutics LLC
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and…
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825352
- Testing
- Carmellose eye drops
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.
Keratoconjunctivitis Sicca, Dry Eye Disease
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry…
- Trial name
- NCT02254265
- Testing
- OTX-101 0.05%, OTX-101 0.09%, Vehicle
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
- Trial name
- NCT00987727
- Testing
- carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi)
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Allergan
Keratoconjunctivitis Sicca
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.
- Trial name
- NCT00128245
- Testing
- Pimecrolimus, Vehicle
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Novartis
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface.
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05807360
- Testing
- Hyaluronic acid eye drops
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye, Kerato Conjunctivitis Sicca
A Study Evaluating the Safety of the Nasal Pump
The objective of this study is to determine the safety of the Tyrvaya nasal pump.
- Trial name
- NCT06329687
- Testing
- Tyrvaya Nasal Pump
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oyster Point Pharma, Inc.
Keratoconjunctivitis Sicca, Dry Eye
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
- Trial name
- NCT03925727
- Testing
- Tavilermide ophthalmic solution
- Where
- 22 sites in United States
- Volunteers
- 623 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Keratoconjunctivitis Sicca
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02139033
- Testing
- Retaine™
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Ocusoft, Inc.
Dry Eye, Dry Eyes Chronic
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface…
- Conditions
- Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Trial name
- NCT06379685
- Testing
- PRO-190, Systane Ultra®
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
Safety Study of Tivanisiran to Treat Dry Eye
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
- Trial name
- FYDES (NCT05310422)
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 25 sites in United States
- Volunteers
- 301 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease
Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops
The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.
- Trial name
- NCT07540884
- Testing
- Tears Naturale Free lubricating eye drops, Tears Naturale II lubricating eye drops
- Where
- 6 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Alcon Research
Dry Eye
A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
Objectives: Primary To determine the safety and tolerability of escalating doses of RU-101 for 4 weeks in patients with severe dry eye Secondary To explore the efficacy of RU-101 To explore optimal endpoints for future studies
- Trial name
- NCT01843894
- Testing
- RU-101
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- R-Tech Ueno, Ltd.
Dry Eye
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
- Trial name
- NCT01129856
- Testing
- Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
- Where
- 5 sites in United States
- Volunteers
- 198 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.
- Trial name
- NCT02117687
- Testing
- carboxymethylcellulose 0.5%/glycerin 0.9%, sodium hyaluronate 0.18%
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 80 people
- Sponsor
- Allergan